Wealthcare Advisory Partners LLC Purchases 17,102 Shares of Abbott Laboratories $ABT

Wealthcare Advisory Partners LLC boosted its position in Abbott Laboratories (NYSE:ABT) by 135.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 29,762 shares of the healthcare product maker’s stock after purchasing an additional 17,102 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Abbott Laboratories were worth $3,729,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories in the third quarter worth approximately $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $31,000. Delos Wealth Advisors LLC bought a new position in Abbott Laboratories in the 2nd quarter worth $32,000. Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories during the third quarter valued at $33,000. Finally, Copia Wealth Management purchased a new stake in Abbott Laboratories in the third quarter worth about $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ABT. Oppenheimer cut their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Piper Sandler reduced their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research note on Friday, January 23rd. Citigroup dropped their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Daiwa Securities Group decreased their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Freedom Capital raised Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $104.12 on Friday. The company has a market cap of $181.35 billion, a price-to-earnings ratio of 27.99, a PEG ratio of 1.65 and a beta of 0.74. Abbott Laboratories has a 1 year low of $102.41 and a 1 year high of $139.06. The stock’s 50 day simple moving average is $110.82 and its two-hundred day simple moving average is $122.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same period last year, the firm posted $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Activity at Abbott Laboratories

In other news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last ninety days. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.